New drug cocktail aims to shrink lung tumors before surgery
NCT ID NCT07269782
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tests two drugs—HLX43 and serplulimab—given before surgery to people with stage II-IIIB non-small cell lung cancer. The goal is to see if the combination can reduce tumor size, making surgery more effective. About 60 participants will be enrolled to evaluate safety and how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX43 (an antibody-drug conjugate targeting PD-L1) combined with serplulimab (an anti-PD-1 antibody)
What this could lead to
If successful, this combination could shrink lung tumors before surgery, potentially improving surgical outcomes and long-term control of the disease.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to all patients. The combination may cause side effects or fail to improve outcomes compared to standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact